Akebia Therapeutics Inc
F:AX9
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Akebia Therapeutics Inc
F:AX9
|
US |
|
Washington H Soul Pattinson and Company Ltd
F:WD3
|
AU |
Akebia Therapeutics Inc
Akebia Therapeutics is a drug company focused on kidney disease. It develops and sells prescription medicines for people with chronic kidney conditions, especially patients who have anemia tied to kidney failure or treatment. Its products are used through doctors and dialysis centers, so the company’s customers are the medical providers and health systems that prescribe and dispense the drugs to patients. The company makes money by selling its approved medicines and by getting paid when those treatments are used in the healthcare system. In this kind of business, the key work is developing a drug, getting it approved by regulators, and then building adoption with nephrologists, dialysis providers, and pharmacy channels. Akebia’s role is narrower than a broad drugmaker: it is concentrated on a specific set of kidney-related treatments rather than a wide portfolio of medicines across many diseases. That focus makes the business easier to understand but also more dependent on a small number of products and the physicians who treat kidney patients. Its success depends on whether those treatments remain useful, reimbursed by insurers, and trusted by doctors who manage chronic kidney disease and dialysis care.
Akebia Therapeutics is a drug company focused on kidney disease. It develops and sells prescription medicines for people with chronic kidney conditions, especially patients who have anemia tied to kidney failure or treatment. Its products are used through doctors and dialysis centers, so the company’s customers are the medical providers and health systems that prescribe and dispense the drugs to patients.
The company makes money by selling its approved medicines and by getting paid when those treatments are used in the healthcare system. In this kind of business, the key work is developing a drug, getting it approved by regulators, and then building adoption with nephrologists, dialysis providers, and pharmacy channels. Akebia’s role is narrower than a broad drugmaker: it is concentrated on a specific set of kidney-related treatments rather than a wide portfolio of medicines across many diseases.
That focus makes the business easier to understand but also more dependent on a small number of products and the physicians who treat kidney patients. Its success depends on whether those treatments remain useful, reimbursed by insurers, and trusted by doctors who manage chronic kidney disease and dialysis care.
Vafseo launch: Vafseo net product revenue reached $15.8 million in Q1 2026, the highest quarter to date, helped by broader prescribing and a bigger patient base.
Patient growth: Management said patients on Vafseo rose 60% sequentially to nearly 7,500, with the strongest new-start quarter since launch.
Observed dosing: The company said adoption is being driven by dialysis organizations shifting to observed, 3-times-weekly dosing, which it believes supports better adherence and future growth.
Mixed revenue: Total revenue fell to $53.5 million, as higher Vafseo sales were more than offset by lower Auryxia revenue amid increasing generic competition.
Pipeline push: Akebia highlighted progress in praliciguat, AKB-097, and AKB-9090, with several data readouts expected in 2027.
Cash runway: Cash and cash equivalents were $162.6 million at quarter-end, and management said existing cash plus operating cash flow should fund the current plan for at least 2 years.
